346 related articles for article (PubMed ID: 19380767)
1. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40.
Khong A; Cleaver AL; Fahmi Alatas M; Wylie BC; Connor T; Fisher SA; Broomfield S; Lesterhuis WJ; Currie AJ; Lake RA; Robinson BW
BMC Cancer; 2014 Dec; 14():969. PubMed ID: 25518732
[TBL] [Abstract][Full Text] [Related]
3. Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model.
Khong A; Brown MD; Vivian JB; Robinson BW; Currie AJ
J Immunother; 2013 Sep; 36(7):365-72. PubMed ID: 23924788
[TBL] [Abstract][Full Text] [Related]
4. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance.
Thatcher TH; Luzina I; Fishelevich R; Tomai MA; Miller RL; Gaspari AA
J Invest Dermatol; 2006 Apr; 126(4):821-31. PubMed ID: 16439962
[TBL] [Abstract][Full Text] [Related]
5. Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade.
Lu H; Wagner WM; Gad E; Yang Y; Duan H; Amon LM; Van Denend N; Larson ER; Chang A; Tufvesson H; Disis ML
J Immunol; 2010 May; 184(9):5360-7. PubMed ID: 20308630
[TBL] [Abstract][Full Text] [Related]
6. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN.
Ahonen CL; Doxsee CL; McGurran SM; Riter TR; Wade WF; Barth RJ; Vasilakos JP; Noelle RJ; Kedl RM
J Exp Med; 2004 Mar; 199(6):775-84. PubMed ID: 15007094
[TBL] [Abstract][Full Text] [Related]
7. CD4
Doorduijn EM; Sluijter M; Salvatori DC; Silvestri S; Maas S; Arens R; Ossendorp F; van der Burg SH; van Hall T
Cancer Immunol Res; 2017 Aug; 5(8):642-653. PubMed ID: 28637878
[TBL] [Abstract][Full Text] [Related]
8. Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination.
Chuang CM; Monie A; Hung CF; Wu TC
J Biomed Sci; 2010 Apr; 17(1):32. PubMed ID: 20426849
[TBL] [Abstract][Full Text] [Related]
9. A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.
Adlard AL; Dovedi SJ; Telfer BA; Koga-Yamakawa E; Pollard C; Honeychurch J; Illidge TM; Murata M; Robinson DT; Jewsbury PJ; Wilkinson RW; Stratford IJ
Int J Cancer; 2014 Aug; 135(4):820-9. PubMed ID: 24390981
[TBL] [Abstract][Full Text] [Related]
10. Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer.
Koga-Yamakawa E; Dovedi SJ; Murata M; Matsui H; Leishman AJ; Bell J; Ferguson D; Heaton SP; Oki T; Tomizawa H; Bahl A; Takaku H; Wilkinson RW; Harada H
Int J Cancer; 2013 Feb; 132(3):580-90. PubMed ID: 22733292
[TBL] [Abstract][Full Text] [Related]
11. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase.
Jackaman C; Lansley S; Allan JE; Robinson BW; Nelson DJ
Int Immunol; 2012 Jun; 24(6):357-68. PubMed ID: 22354912
[TBL] [Abstract][Full Text] [Related]
12. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.
Jackaman C; Nelson DJ
Cancer Immunol Immunother; 2012 Apr; 61(4):549-60. PubMed ID: 22002241
[TBL] [Abstract][Full Text] [Related]
14. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
[TBL] [Abstract][Full Text] [Related]
15. Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12.
Caminschi I; Venetsanakos E; Leong CC; Garlepp MJ; Robinson BW; Scott B
Am J Respir Cell Mol Biol; 1999 Sep; 21(3):347-56. PubMed ID: 10460752
[TBL] [Abstract][Full Text] [Related]
16. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells.
Forward NA; Furlong SJ; Yang Y; Lin TJ; Hoskin DW
J Leukoc Biol; 2010 Jan; 87(1):117-25. PubMed ID: 19843574
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
18. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
[TBL] [Abstract][Full Text] [Related]
19. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
20. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice.
Ma F; Zhang J; Zhang J; Zhang C
Cell Mol Immunol; 2010 Sep; 7(5):381-8. PubMed ID: 20543857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]